Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Ranking of 20 Drug Companies Shows Sales Force Effectiveness Reaching Plateau
- A ranking of 20 drug companies by sales and marketing productivity shows that 10 companies saw upward trends in effectiveness in Q2 2009. Last quarter, 13 companies had upward trends. The numbers indicate that companies have started to reach a plateau in their efforts to wring more revenues out of...
- Blog posts 2009-08-07
- Will Online Rx Get Easier to Swallow?
- As pharmaceuticals struggle to get doctors to take their medicine, they ignore the valuable branding resources available on the web. Most pharmaceutical branding rarely goes beyond the trademarked name, at least for patients. But among the professional medical community, drug companies embrace the scope for building a more complete brand...
- White papers 2002-01-07
- Drug Companies' Health Education Campaigns No Longer Speak Spanish
- For the first time in at least three years, drug companies have spent zero dollars on Spanish-language television for their unbranded health education ads, Nielsen-Monitor Plus reports. The wholescale write-off of Hispanic TV draws attention to how little Spanish-language provision there is in drug marketing. Of the...
- Blog posts 2008-10-03
- Ranking of 20 Drug Companies by Sales Force Effectiveness Shows Improvement in Q1
- A ranking of 20 drug companies on sales and marketing productivity shows upward trends in effectiveness in Q1 2009. At the top of the table is AIDS drug specialist Gilead. At the bottom of the table is vanity pharma play Medicis. by Jim Edwards
- Blog posts 2009-05-14
- Wyeth v. Levine's Unintended Consequences: Prescription Data-Mining Banned in Vermont
- A federal court in Vermont has upheld a law preventing drug companies from "data-mining" prescription information from pharmacies. The court cited the U.S. Supreme Court's Wyeth v. Levine anti-preemption ruling as one of its reasons in doing so, suggesting that the Wyeth decision will consequences far beyond personal injury class-actions....
- Blog posts 2009-04-27
- NPR Producer: Goodwin Broke "Ironclad" Contract Over GSK Cash; Pitts Didn't Disclose Ties
- The producer of an NPR radio show has accused the show's host, Fred Goodwin, of breaking his contract by failing to disclose his ties to drug companies. The producer also denies that Peter Pitts, a former FDA official and an executive at Manning, Selvage & Lee, a...
- Blog posts 2009-03-09
- Novartis, Boehringer Start Using Twitter Accounts
- AstraZeneca, Novartis, Vertex Pharmaceuticals and Boehringer Ingelheim have started experimenting with Twitter with varying degrees of enthusiasm, reports Pharmaceutical Executive. Drug companies have so far looked at social media with a mixture of fear and loathing. They believe perhaps wrongly that giving consumers more opportunities to talk...
- Blog posts 2009-02-18
- Goodwin, Biederman on Counter-Attack in Drug Funding Transparency Scandal
- Two prominent doctors accused of failing to be transparent about payments they took from drug companies have gone on the counter-attack. NPR host Dr. Fred Goodwin wrote a letter to the New York Times and an email to Daniel Carlat's psychiatry blog. And Dr. Joseph Biederman, the Boston psychiatrist who...
- Blog posts 2008-12-08
- Fred Goodwin Loses NPR Gig Over GlaxoSmithKline Ties
- NPR says it will cancel the psychology show The Infinite Mind from its satellite radio service following a report in the New York Times that host Fred Goodwin took $1.3 million from drug companies such as GlaxoSmithKline and didn’t declare that to his listeners. The news will not come as...
- Blog posts 2008-11-21
- Pharma Roundup: Schering-Plough Surveys Investors, Wyeth Defended, and More
- Schering-Plough shareholders to have say on executive compensation, U.S. drug sales predictions lowered, McCain and Obama both promise hard line on Big Pharma. Also: two lawyers condemn unfounded anti-Wyeth opinions. by John Maas
- Blog posts 2008-10-29
- Academic Drug Conflicts Probe: "Problems With Transparency Are Everywhere"
- Emory. Harvard. Stanford. Brown. The University of Texas. The University of Cincinnati. It's a roll call of the nation's most prominent schools of psychiatry. But top researchers and professors at those schools could, essentially, be rented out by drug companies for hundreds of thousands of dollars. Then, those academics allegedly...
- Blog posts 2008-10-03
Additional Resources
- J&J and Risperdal: New Claims of Kickbacks and Fraudulent Marketing
- The news on Risperdal continues to get worse for Johnson & Johnson and its antipsychotic unit, Janssen Pharmaceuticals. Texas officials filed suit against the company alleging Medicaid fraud, kickbacks and improper marketing of the drug to children and the poor in that state. J&J denies the claims. ...
- Blog posts 2008-12-17
- Our Favorite Drug Company Conference Call Tap Dancers
- Drug company conference calls with Wall Street are often dull or baffling -- a fast tide of numbers and facts extracted by spreadsheet jocks. But they're often the only chance we have to hear CEOs and other senior execs talking without the benefit of prepared remarks. Every once in while...
- Blog posts 2008-11-13
- Open Biosystems Appoints Ray "Woody" Woodward Vice President of Sales and Marketing
- Seasoned Medical Device Sales and Marketing Leader to Enhance Brand of Cutting-Edge Drug Discovery Tools HUNTSVILLE, Ala. -- Open Biosystems, Inc., focused on the commercialization of leading-edge life science research tools for drug discovery, today announced the appointment of Ray E. "Woody" Woodward as Vice President of Sales and...
- Research articles 2006-11-02
- FDA Expands Use of Convera Search Technology for Drug Review and Approval Process
- VIENNA, Va. -- Convera (NASDAQ:CNVR), a leading provider of search and categorization software for enterprises and government agencies, today announced expanded use of the company's RetrievalWare search technology by approximately 2,500 scientific review staff within the Center for Drug Evaluation and Research CDER at the FDA. The FDA's CDER uses...
- Research articles 2004-06-22
- Auriga Details Business Vision to Capitalize on Revenue Opportunities in Pharmaceutical Marketplace in New Investor Fact Sheet; Company to Host Investor Conference Call to Discuss Acquisitions, New Drug Development and Marketing Initiatives
- NORCROSS, Ga. -- Auriga LaboratoriesTM, Inc. (OTCBB:ARGA), a specialty pharmaceutical company committed to high-growth revenues through acquisition of valuable brand portfolios and innovative drug development programs, has released an Investor Fact Sheet detailing the Company's strategic initiatives to address high-growth revenue opportunities through proprietary product development and strategic brand name...
- Research articles 2006-08-01
- GlaxoSmithKline pays $150M to settle drug pricing fraud case
- GlaxoSmithKline has paid over $150 million to resolve allegations that the company violated the False Claims Act through fraudulent drug pricing and marketing of two anti-emetic drugs, Zofran and Kytril, used primarily in conjunction with oncology and radiation treatment.
- Research articles 2005-09-29
- Electropharmacology Announces Closing of Agreements to Restructure Itself Into a Biotechnology Company Focused On Drug Design and Drug Delivery
- POMPANO BEACH, Fla.--BW HealthWire--Aug. 19, 1998-- Electropharmacology, Inc. EPi (NASDAQ OTC BB:EPHI) announced today the closing of three previously announced transactions - the acquisitions of Gemini Biotech, Ltd. Gemini of The Woodlands, Texas and HealthTech Development Inc. HTD of Dallas, Texas, and the divestiture of the SofPulse device inventory and...
- Research articles 1998-08-19
- Electropharmacology Announces Closing of Agreements to Restructure Itself Into a Biotechnology Company Focused On Drug Design and Drug Delivery
- POMPANO BEACH, Fla.--BW HealthWire--Aug. 19, 1998-- Electropharmacology, Inc. EPi (NASDAQ OTC BB:EPHI) announced today the closing of three previously announced transactions - the acquisitions of Gemini Biotech, Ltd. Gemini of The Woodlands, Texas and HealthTech Development Inc. HTD of Dallas, Texas, and the divestiture of the SofPulse device inventory and...
- Research articles 1998-08-19
- Galt Names Bruce Hayden Chief Financial Officer; New CFO to Strengthen Fast-Growing Drug Safety Company's Executive Team
- Business/Technology Editors and Health/Medical Writers STERLING, Va.--BW HealthWire--June 17, 2002 Galt Associates, Inc., provider of drug safety and marketing software and services, announced today that it has appointed Bruce Hayden as chief financial officer. Mr. Hayden will play a prominent role in driving Galt's revenue, which experienced a...
- Research articles 2002-06-17
- << Previous
- page 1 of 1
- Next >>
Presented by American Express